CA2211324A1 - Alpha-foetoproteine humaine recombinante et ses utilisations - Google Patents

Alpha-foetoproteine humaine recombinante et ses utilisations

Info

Publication number
CA2211324A1
CA2211324A1 CA002211324A CA2211324A CA2211324A1 CA 2211324 A1 CA2211324 A1 CA 2211324A1 CA 002211324 A CA002211324 A CA 002211324A CA 2211324 A CA2211324 A CA 2211324A CA 2211324 A1 CA2211324 A1 CA 2211324A1
Authority
CA
Canada
Prior art keywords
fetoprotein
human alpha
cell
recombinant human
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002211324A
Other languages
English (en)
Other versions
CA2211324C (fr
Inventor
Robert A. Murgita
Richard Boismenu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Individual filed Critical Individual
Publication of CA2211324A1 publication Critical patent/CA2211324A1/fr
Application granted granted Critical
Publication of CA2211324C publication Critical patent/CA2211324C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

De façon générale, on divulgue des méthodes pour inhiber la prolifération des cellules immunitaires autoréactives chez un mammifère, comportant l'administration au mammifère d'une quantité thérapeutiquement efficace d'une alpha-foetoprotéine humaine recombinante ou d'un fragment anti-prolifération des cellules immunitaires ou d'un analogue de cette dernière; des méthodes pour inhiber un néoplasme chez un mammifère, comportant l'administration au mammifère d'une quantité thérapeutiquement efficace d'une alpha-foetoprotéine humaine recombinante ou d'un fragment anti-néoplasme ou d'un analogue de cette dernière; ainsi que des méthodes de culture cellulaire, comportant l'utilisation d'un milieu contenant de l'alpha-foetoprotéine humaine ou un fragment ou un analogue de cette dernière.
CA2211324A 1995-01-24 1996-01-24 Alpha-foetoproteine humaine recombinante et ses utilisations Expired - Lifetime CA2211324C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US37731195A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US37731695A 1995-01-24 1995-01-24
US08/377,311 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/377,316 1995-01-24
US08/377,317 1995-01-24
US08/377,309 1995-01-24
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
US08/505,012 1995-07-21
PCT/US1996/000996 WO1996022787A1 (fr) 1995-01-24 1996-01-24 Alpha-f×toproteine humaine recombinante et ses utilisations

Publications (2)

Publication Number Publication Date
CA2211324A1 true CA2211324A1 (fr) 1996-08-01
CA2211324C CA2211324C (fr) 2012-07-10

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2211324A Expired - Lifetime CA2211324C (fr) 1995-01-24 1996-01-24 Alpha-foetoproteine humaine recombinante et ses utilisations

Country Status (7)

Country Link
EP (1) EP0805687A4 (fr)
JP (2) JPH10513347A (fr)
CN (1) CN1150030C (fr)
AU (1) AU700975B2 (fr)
CA (1) CA2211324C (fr)
HK (1) HK1010153A1 (fr)
WO (1) WO1996022787A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
JP3816959B2 (ja) * 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
ATE380467T1 (de) * 1999-01-06 2007-12-15 Merrimack Pharmaceuticals Inc Expression von ausgeschiedenem, menschlichem alpha-fetoprotein in transgenen tieren
DE60041189D1 (de) * 1999-07-12 2009-02-05 Univ Bruxelles Genetisch modifiziertes nichthumanes tier mit mangel in alpha-fetoprotein
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
CN1255427C (zh) * 2000-02-10 2006-05-10 加利福尼亚州大学董事会 用于治疗肝细胞癌的方法和组合物
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20060111289A1 (en) * 2004-09-09 2006-05-25 Serometrix, Llc, Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
EP2111230A4 (fr) * 2006-12-19 2010-11-17 Merrimack Pharmaceuticals Inc Coadministration d'alpha-foetoproteine et d'un agent immunomodulateur pour traiter la sclerose en plaques
WO2008113970A2 (fr) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0356399A3 (fr) * 1988-08-26 1991-03-20 Sandoz Ag Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
WO1993005774A1 (fr) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides
CA2120131A1 (fr) * 1991-09-27 1994-05-11 Robert A. Murgita Expression et purification d'alphafoetoproteine humaine clonee
DE59509887D1 (de) * 1994-09-26 2002-01-10 Infineon Technologies Ag Koppelanordnung zum optischen aneinanderkoppeln eines oeic-bausteins und optischer fasern

Also Published As

Publication number Publication date
CN1179106A (zh) 1998-04-15
JP2008073041A (ja) 2008-04-03
AU4903596A (en) 1996-08-14
CA2211324C (fr) 2012-07-10
AU700975B2 (en) 1999-01-14
WO1996022787A1 (fr) 1996-08-01
EP0805687A4 (fr) 2000-05-31
JPH10513347A (ja) 1998-12-22
HK1010153A1 (en) 1999-06-17
CN1150030C (zh) 2004-05-19
EP0805687A1 (fr) 1997-11-12

Similar Documents

Publication Publication Date Title
CA2211324A1 (fr) Alpha-foetoproteine humaine recombinante et ses utilisations
Casey et al. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography
AU725238B2 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
FI103181B (fi) Uusi vasta-aine ja siihen liittyvät vasta-ainekonjugaatit, DNA-sekvens sit, ilmentämisvehikkelit ja solut
CA2287872A1 (fr) Compositions immunogenes dirigees contre le recepteur de cck-b/gastrine et procede de traitement des tumeurs
CA2082272A1 (fr) Unites a site de reconnaissance moleculaire
EP0334165A2 (fr) Anticorps monoclonaux
KR20200143366A (ko) 수식 항체 및 방사성 금속 표지 항체
US6355444B1 (en) Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and uses therefor
IE66494B1 (en) Granulocyte-colony stimulating factor receptors
US6008319A (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
WO1997012913A1 (fr) Proteine de liaison aux glucides d'origine tumorale
CA2240409A1 (fr) Genes de chemokine cx3c mammalienne
AU722904B2 (en) Novel polynucleotides PANC1A and PANC1B associated with pancreatic cancer
WO1998008866B1 (fr) Bau, une proteine interactive associee a la sequence bin1, et utilisations
US5496705A (en) Monoclonal antibody specific for rat synaptophysin
AU596670B2 (en) Assays and antibodies for n-myc proteins
Lam Treatment of B-cell lymphoma using peptides. A novel concept.
Rathjen et al. Selective enhancement of tumour necrosis factor activity: mapping regions with monoclonal antibodies
EP0931836B1 (fr) Peptide dérivé de l'interleukine-2 humaine pouvant accroître la perméablilté vasculaire et les immunoconjugués en dérivant
JPH11508235A (ja) 腫瘍関連エピトープ
US20040156824A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
Ozker Current developments in single photon radiopharmaceuticals for tumor imaging
DE19738710A1 (de) Verwendung von TIRC7 zur Herstellung von Mitteln zur Inhibition der Immunantwort
FI103477B (fi) Menetelmä terapeuttisesti käyttökelpoisen vasta-aineen tai vasta-ainef ragmentin valmistamiseksi

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160125